Evolocumab
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Evolocumab: From LDL-Cholesterol Lowering to Symptomatic Hemophilia in Female Carriers
One-Sentence Summary
Evolocumab (marketed as REPATHA) is a PCSK9-neutralizing monoclonal antibody that lowers LDL cholesterol. The TxGNN model predicts it may be effective for symptomatic hemophilia in female carriers, but 0 clinical trials and 0 publications support this direction. It is a model-only prediction with no plausible mechanistic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in the license records (LDL-C lowering, based on the drug’s mechanism class) |
| Predicted New Indication | Symptomatic form of hemophilia in female carriers |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 4 (all records under BLA125522) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the source record. Evolocumab is a monoclonal antibody that neutralizes PCSK9. This increases LDL receptor recycling and lowers LDL-C.
Hemophilia in female carriers is a coagulation disorder caused by reduced factor VIII or IX production or function. Evolocumab has no known role in coagulation factor synthesis, activity, or replacement, so no plausible mechanistic link was identified.
The high TxGNN score (0.998) reflects a knowledge-graph pattern only, and it is likely an artifact. No trial or publication supports it. The other five predictions are also unsupported:
- Familial apolipoprotein C-II deficiency (99.50%) is the most biologically adjacent, as a lipid-metabolism disorder. Evolocumab mainly lowers LDL-C and does not address the lipoprotein lipase activation defect.
- Thrombocytopenic purpura, factor XI deficiency and hemophilia A with vascular abnormality have no mechanistic link.
- “Disease of catalytic activity” is a non-specific ontology category, not an actionable indication.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| BLA125522 | REPATHA (Amgen USA Inc.) | Injection, solution | Not listed in the record |
Four license records exist under this BLA. They are identical in the data, so they are shown once.
Safety Considerations
- Drug Interactions: No interaction records were found in the queried database.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is model-only (L5) with no trials or literature. Evolocumab’s PCSK9 mechanism has no plausible connection to coagulation factor deficiency. Its marketed status does not offset this lack of evidence.
To proceed, the following is needed:
- A mechanistic hypothesis linking PCSK9 inhibition to coagulation, supported by preclinical data
- A systematic literature and trial search showing any signal for this indication
- Package insert warnings and contraindications, plus mechanism of action data, to complete the record
- If a lipid-related direction is pursued, re-evaluating familial apolipoprotein C-II deficiency first
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.